Alnylam Pharmaceuticals, Inc. ALNY
We take great care to ensure that the data presented and summarized in this overview for ALNYLAM PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALNY
View all-
Capital World Investors Los Angeles, CA16.7MShares$5.43 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.23 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.09 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.32 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.43 Billion0.79% of portfolio
-
Baillie Gifford & CO3.66MShares$1.19 Billion0.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.51MShares$1.14 Billion0.12% of portfolio
-
State Street Corp Boston, MA3.37MShares$1.09 Billion0.04% of portfolio
-
Dodge & Cox San Francisco, CA3.35MShares$1.09 Billion0.55% of portfolio
-
Wellington Management Group LLP Boston, MA2.61MShares$846 Million0.14% of portfolio
Latest Institutional Activity in ALNY
Top Purchases
Top Sells
About ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at ALNY
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 01
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
7,763
+26.74%
|
-
|
Jun 02
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,297
-28.28%
|
$5,904,882
$306.0 P/Share
|
Jun 02
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,297
+13.04%
|
$2,277,046
$118.59 P/Share
|
May 30
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,640
-21.4%
|
$9,650,200
$305.0 P/Share
|
May 30
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,640
+18.03%
|
$3,733,520
$118.59 P/Share
|
May 16
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
8,376
-14.61%
|
-
|
May 15
2025
|
Michael W Bonney Director |
SELL
Open market or private sale
|
Direct |
11,250
-3.56%
|
$3,105,000
$276.05 P/Share
|
May 15
2025
|
Michael W Bonney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+28.62%
|
$1,473,750
$131.21 P/Share
|
May 08
2025
|
Amy W Schulman Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+6.09%
|
-
|
May 08
2025
|
Colleen F Reitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
May 08
2025
|
David E I Pyott Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+45.97%
|
-
|
May 08
2025
|
Peter N Kellogg Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
May 08
2025
|
Margaret A Hamburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+45.97%
|
-
|
May 08
2025
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
May 08
2025
|
Michael W Bonney Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+4.41%
|
-
|
May 08
2025
|
Dennis A Ausiello Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+45.97%
|
-
|
May 08
2025
|
Carolyn R Bertozzi Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
May 08
2025
|
Charles Elliott Sigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
775
+50.0%
|
-
|
May 02
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
41,311
-41.88%
|
-
|
Apr 16
2025
|
Colleen F Reitan Director |
SELL
Open market or private sale
|
Direct |
36
-100.0%
|
$8,352
$232.86 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 125K shares |
---|---|
Exercise of conversion of derivative security | 220K shares |
Open market or private purchase | 36 shares |
Open market or private sale | 262K shares |
---|---|
Bona fide gift | 49.7K shares |